Home | Welcome to Contract Pharma   
Last Updated Wednesday, May 27 2015


Financial Report: AbbVie

By Kristin Brooks

Published January 31, 2014
4Q Revenues: $5.1 billion (-2%)
4Q Earnings:
$1.1 billion (-27%)
FY Revenues: $18.8 billion (+2%)
FY Earnings: $4.1 billion (-22%)
Comments: Global Humira sales increased 13% to $3.0 billion in the quarter. U.S. Humira sales grew 18% to $1.7 billion. Synagis sales were $314 million, down 6%. AndroGel sales were down 21% to $289 million. Kaletra sales were $228 million, down 9%. Lupron sales were $209 million, down 1%. Synthroid sales were up 13% to $189 million. Niaspan and TriCor/Trilipix sales were down 89% and 85% respectively, due to generic competition. R&D expenses were up 17% to $798 million in the quarter.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On